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Why did we sequence the human
genome? Aside from those who
genuinely want to know the
precise function of each and every
human gene — a small minority of
people, to be sure — most of us
see the principle value of the
genome project in its utility for
improving human health. After all,
once we identify genes we can
design better drugs, develop
better diagnostics, and gain a
better understanding of the roles
of genetic risk factors in disease.
But to accomplish these goals we
also need to understand
something the sequencing project
only started to uncover: genetic
diversity.
This is no new challenge,
especially for human geneticists
trying to map disease genes. It is
true that genetic diversity in the
form of RFLPs and SNPs has been
successfully put to work in family-
based linkage studies, yielding
(often through heroic efforts) the
genes behind many single locus,
Mendelian disorders. These
diseases are generally quite rare,
presumably for the simple reason
that single mutations with strong
phenotypic effects are likely to be
selected against in the course of
evolution. The trouble is that the
power of linkage analysis falls off
rapidly once multiple disease
genes with modest effects are
involved, and efforts to use
linkage analysis and positional
cloning to identify genes behind
common diseases such as heart
disease, diabetes, asthma, and
schizophrenia have generally not
met with success. While direct
association studies provided a
tactic that theoretically had the
power to unearth the genes
behind these diseases, the
prospect of genotyping thousands
of individuals for a multitude of
SNPs posed a serious practical
and financial barrier for
researchers.
Fortunately, nature appears to
have provided a shortcut of sorts.
In the last couple of years it has
become increasingly clear that
SNPs, which form the basis of
most genetic differences between
individuals, are very often in a
state of linkage disequilibrium (LD)
with their surrounding DNA — that
is, blocks of neighboring SNPs are
inherited together, effectively
defining a haplotype for the
corresponding region. This is
great news for finding disease
genes because it means a unique
SNP or a unique combination of
SNPs could stand in for the entire
haplotype in a genetic test,
making large-scale association
studies much more economically
feasible. But getting to this
efficient stage will require a
tremendous amount of initial work
to build a haplotype map from
which informative SNPs for each
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common haplotype can be
identified.
Given the great potential of
haplotype-based genome scans
to aid our understanding of
common diseases, it’s not
surprising that plans for a large,
publicly funded haplotype
mapping project are brewing at
the NIH’s National Human
Genome Research Institute, a
project likely to be undertaken in
collaboration with groups such as
the Wellcome Trust and the SNP
Consortium among others.
According to Lisa Brooks,
Program Director of the NHGRI’s
Human Genetic Variation
Program, initial plans for the
project were set in motion at a
meeting in July, where working
groups were formed to explore
the substantial technical, logistical
and ethical challenges posed by a
haplotype mapping endeavor. 
Given the great potential of
haplotype-based genome
scans to aid our
understanding of common
diseases, it’s not surprising
that plans for a large scale
project are brewing...
Significant ethical considerations
are warranted because to
produce a whole genome
haplotype map that includes all
common haplotypes found in
human populations, the project
will need to draw genetic
information from a diversity of
ethnic groups. This is due to the
fact that LD and SNP frequencies
are influenced by events in
population history that include
bottlenecks, genetic isolation and
admixture, and the extent to
which haplotype structure varies
between and among groups has
only recently begun to be
explored. A main challenge for the
project will be achieving
inclusiveness while avoiding the
perception of exploitation,
according to Ellen Wright Clayton,
a member of one of the project’s
working groups and an expert in
bioethics and law at Vanderbilt
University. Community
involvement is key, according to
Clayton. “The driving force behind
this is the recognition that science
is a collaboration.”
Chief among the technical
issues facing the project at this
stage is simply the fact that the
nature of LD across the genome is
variable and remains largely
unknown, and the number of
SNPs and population pools
required for the construction of a
useful, inclusive haplotype map is
still unclear. According to Brooks,
the methods working group set
up at the July meeting is currently
undertaking a broad analysis of
the SNP data already available
from between 10 and 50 genomic
regions from a small number of
population groups, looking to
answer basic questions such as
how best to define haplotype
blocks in the first place. The plan
is then to move onto a pilot
project analysing SNPs from the
same regions from an extended
collection of 12 or 13 groups to
get a clearer idea of how
haplotype structure varies across
populations. 
Critical to these initial efforts,
says Brooks, is the flurry of
ongoing research into human
haplotype structure being
undertaken by numerous groups
— see recent papers by Daly
et al., Rioux et al., Johnson et al.,
Jeffreys et al., and Goldstein in
last October’s Nature Genetics,
and other studies appearing in the
next few months. 
Concurrent with the pilot efforts
will be the upcoming initiation of
the large scale project, which will
focus at first on SNP mapping in
three populations — most likely
African-American, Chinese-
American and European-American
— in collaboration with long-
standing partnerships between
NHGRI and local community
groups in the US. Eventually,
according to Brooks, the findings
of the pilot haplotype projects will
allow informed decisions to be
made about the best populations
to add to the large scale project
to ensure that the haplotype map
being developed is informative
and inclusive. While the projected
timeframe is uncertain, speed is a
priority, and requests for
applications for the project will be
issued by the NHGRI sometime
this spring, with a goal of funding
beginning in early fall.
In the meantime, SNP discovery
and haplotype analysis continue
to be hot areas of activity within
the biotech community,
particularly at companies such as
Millenium, Celera, Genaissance
and Perlegen, and high impact
work on haplotype structure from
biotech groups is being published
(see Stephens et al., Science 293,
489–493 and Patil et al., Science
294, 1719–1723).
In contrast to the genome-wide
approach planned by the public
project, biotech groups often —
though not always — focus their
SNP discovery and haplotype
analysis on gene loci or even
particular gene families suspected
of playing a role in disease or drug
response.
The hope is that targeted
approaches will have the potential
to identify some functionally
important SNPs in a relatively
short term, whereas an
advantage of a genome-wide
effort is that it would overcome,
and eventually help answer,
questions regarding the functional
importance of SNPs in distal
regulation of genes.
While the methods and short
term goals of the private groups
may differ from those of public
efforts, collaboration between the
two communities is likely to be
essential to the development of a
information rich haplotype map.
Despite the considerable
unknowns regarding the eventual
requirements for SNP data and
analysis, the chief obstacle for the
haplotype map’s development
isn’t technical, but rather financial,
according to David Cox,
Co-founder and Chief Scientific
Officer of Perlegen Sciences.
“This whole endeavor takes a lot
of money, and different people in
different settings are going to be
finding different SNPs and
different pieces of information,”
says Cox. “There will be ways for
that information to be shared.”
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